Key clinical point: Adding cetuximab to radiotherapy and cisplatin does not improve outcomes in patients with locoregionally advanced head and neck carcinoma.
Major finding: The 10-year progression-free survival rate was 43.6% in patients who received radiotherapy plus cisplatin and 40.2% in patients who received cetuximab plus radiotherapy and cisplatin (P = .74). The 10-year overall survival rate was 49.9% and 50%, respectively (P = .36)
Study details: Long-term follow-up of a phase 3 trial including 452 patients with locoregionally advanced head and neck carcinoma.
Disclosures: This research was sponsored by the Radiation Therapy Oncology Group, the National Cancer Institute, NRG Oncology, and Eli Lilly. Dr. Caudell disclosed grants and fees from Varian Medical Systems.
Caudell J et al. Head and Neck Cancers Symposium 2020, Abstract 6.